Dr Jorge Pinto Ferreira

Deputy Head, Antimicrobial Resistance and Veterinary Products Department

How AMU data collection can help to drive action

Global Agenda for Sustainable Livestock (GASL) Webinar Series Antimicrobials in livestock: from scrutinity to action in low-income countries 17 November, 2020 Online seminar

WORLD ORGANISATION FOR ANIMAL HEALTH Protecting animals, preserving our future

OIE World Organisation for Animal Health

- An Intergovernmental Organisation
- Formed in 1924 as the Office International des Epizooties (OIE)
- Mandate to Improve Animal Health, Welfare and Veterinary Public Health

 Sets international standards recognized by the WTO





The OIE Strategy on AMR and the Prudent Use of Antimicrobials

 The OIE Strategy supports the objectives established in the Global Action Plan on antimicrobial resistance and reflects the mandate of the OIE, through four main objectives:



http://www.oie.int/fileadmin/Home/eng/Media_Center/docs/pdf/PortailAMR/EN_OIE-AMRstrategy.pdf

OIE AMU Data Collection





OIE Standards and guideline related to antimicrobial resistance

Terrestrial Animal Health Code



- Ch.6.7. Introduction to the recommendations for controlling antimicrobial resistance
 - Ch.6.8. Harmonisation of national AMR surveillance and monitoring programmes (updated in May 2018)
 - Ch.6.9<u>. Monitoring of the</u> <u>quantities and usage patterns</u> of antimicrobial agents used in food-producing animals (Agreement on definitions)
- Ch.6.10. Responsible and prudent use of antimicrobial agents in veterinary medicine
- Ch.6.11. Risk analysis for AMR arising from the use of antimicrobial agents in animals

Aquatic Animal Health Code



- Ch.6.2. Principles for responsible and prudent use of antimicrobial agents in aquatic animals
- Ch.6.3. Monitoring of the quantities and usage patterns of antimicrobial agents used in aquatic animals
- Ch.6.4. Development and harmonisation of national AMR surveillance and monitoring programmes for aquatic animals
- Ch.6.5. Risk analysis for AMR arising from the use of antimicrobial agents in aquatic animals



https://www.oie.int/en/scientific-expertise/veterinary-products/antimicrobials/



Rounds of the OIE AMU Data Collection



Documents on the OIE Website





OIE Template, Guidance and Calculations

The OIE considered the experience and feedback from Member Countries and annually update the template and guidance document based on requests for clarification from responding Members. The current version of these documents, are available below.

Construction of the second secon	Santine child an execution. Name provie ta eliterative companie challens in pro-10% are aplicate challens in pro-10% are aplicate companies or politicate and any definitions of companies of the sant any definitions of the sant the same same	COC Reconstruction on the line Management of the Management of the	The set of
• • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •		Rest constraints to the second	The second secon
Experimentary of the second seco	der man an der gibt er son der Galer, diesen Annene	See	
Internet to the set of		Guidance for completing the OIE template	Annex to assist in calculations

Oie

2nd OIE Global Conference on Antimicrobial Resistance and Prudent Use of Antimicrobial Agents

Putting Standards into Practice

Marrakesh (Morocco), 29-31 October 2018

RECOMMENDATIONS

https://www.oie.int/amr2018/en/

RECOMMEND TO THE OIE

- To continue updating OIE standards in the OIE Terrestrial and Aquatic Codes relevant to AMR and needed capacities of Member Countries and to complete standards in the OIE Terrestrial and Aquatic Manuals,
- To provide OIE Member Countries, through activities undertaken under the <u>PVS Pathway</u>, with tools and capacity-building activities, with a greater focus on AMR including update of policy and legislation;
- To continue to develop the <u>OIE List of Antimicrobial Agents of Veterinary Importance</u>, considering

 a) the inclusion of antimicrobials only used in companion animals, b) the sub-division of the List
 in the different animal species, and c) the expansion of the List, to include over time antiparasitic
 agents of veterinary importance such as anthelminitics, insecticidal and acaricidal;
- 4. To further develop the <u>OIE data collection</u> on Antimicrobial Agents Intended for Use in Animals, converting the current spreadsheet format to a database system, able to accommodate data submissions by animal species, and its connection to the World Animal Health Information System (WAHIS) and also allowing addition of data from field studies;
- To work with Animal Food Production sectors and institutions such as the World Veterinary Association and related professional bodies for supporting the development of species specific treatment guidelines to be used at sub-regional and national level and the establishment of a global repository of existing clinical treatment guidelines and tools;
- To explore the possibility of building an information system of falsified or substandard drugs in the animal sectors illegally circulating within and between countries and building on the experience of the monitoring systems set up by WHO for drugs designated for human use taking a "One Health" approach;
- 7. To encourage research based on robust methodologies, aiming at comparison of results, that focuses on a better understanding of the dynamics and epidemiology of AMR, from an integrated "One Health" perspective, on the development of priority vaccines and other alternatives to antimicrobials, of proven safety, efficacy and quality and on rapid diagnostic and sensitivity tests specific for veterinary medicine, building on public-private partnerships;
- To explore the opportunity to develop standards or guidelines related to autogenous vaccines and other alternatives to antimicrobials, including guidance for quality, safety and efficacy, as tools to reduce the need to use antimicrobials;
- To develop a Monitoring and Evaluation (M&E) framework to monitor the progress of the implementation of the OIE Strategy on AMR and the Prudent Use of Antimicrobials, adopted by Resolution No. 36 by the OIE World Assembly of Delegates at the 84th General Session of the OIE in 2016;
- To continue to support OIE Member Countries in the development of their communication activities and national action plans involving all animal health stakeholders, specifically supporting capacity building activities for behaviour change initiatives tackling antimicrobial resistance;

- 2 -

Additional assistance in calculations

The OIE Antimicrobial Use Team has updated the tool to assist countries in obtaining kilograms of active ingredients

D	o not change	Optional	Optional	Mandatory	Mandatory	Optional	Optional									Mandatory	Mandatory																				
	OIE ID												Please indicate the purpose of the product,									c	Please in Ani overed by	idicate mals the pr	the oduct												
Nº Ref.	(this ID will be used to provide you with product's baseline information for future rounds)	Data Source Used	ID Product Presentation	Product name	according to its label declaration. (Medical use includes <u>prevention</u> of clinical signs)	Route of administration, according to its label declaration	e Bovine	< Swine	• Sheep	< Gonts	 Poultry Carnelidae 	< Equidae	< Rabbits/Hares	< Bees - Honey	Reputes	 Rish - Carps 	Hish - Salmon or	< Rish - Tilapia	Ash - Cothshes	 Oustoceans 	< Mollascs	Amphubians	< Conines Gánas	. Om amental fish	Number of packages sold, imported, produced, prescribed or used in the <u>period of</u> <u>time declared to OIE</u>	•	Package size	Package size unit	Ac								
-0		Imports	ASFR-20156	Example 1	Vet. Medical use	Parenteral	1															Y	es		1,500	Units	100	ml	Sulfe								
0		Manufacture/Produ	ASFR-20157	Example 2	Growth promotion	Oral	i	Y	(es)			Yes													200	Units	25	kg	Colis								
- 23	1																5						1														
1	2							_	_	_	_	-						_	_	_	-	1	_	_													
3	3	-	0				-		-	-	-				_			-	_			-	-	_					-								
-							i	-	-	-	-	-		_			-	-		-		-	-	-													
			-			-	-	-	-	-	_	-			1			-	-	-	-	-	-	-		_											
-	7							-	-	+		+						+		+			-	-													
8	3	2						-																													
4)					1	î l																		1												
10													1																								
the second se																	and the second se											4	4								

			100			Real of a
35	Precisi 25	3,230.4	623	18.076.0	120148	09101
	Product 1	603.5	12%	15.067.0	100-8 ml	Perentanal
34	PHG0.2	805.0	12%	4.000 0	121.41	0121
13	Product 5	274.0	5%	4,567.0	200.0 4	0-d
18-	Period	\$2.5	15	23.0	253.4	0101
	Product prenis	45.0	15	1,500.0	500.0 g	04
.4	Product avenus	45.0	15	L 300 D	900-0.4	001
	Product prenia	42.0	15	798.0	10 kg	0-d
40	Product 32	41.6	15	2,470.0	100.0.×f	Powter)
29	Product 15	10.0	13	2.140.0	100-8 ed	Persitand



	BE Constitution	Bud reported autocals
luin.	Semple fait and any provide	6.05ameraire
laine	Terestrial had- producing around	Inferinetoine
1-100	Terresis di terre attesta de la constitución Terresista de la constitución estàcia a constitución	holidad magnitus na
1.112	Terrer publicate medicating process	Terrere
Constitue Co C.F.	producing primed	Gehrlesin bersahline
Antonio Marco	Personal field	Brofinacia
Austin	Terrestrial field producing animal	



















								Type of Use	1		Raute of Administration								
Molecule Information			Total		Vet. Medical Use + Growth Promotion		Vet.	Medical Use	Growt	h Promotion	oral			renteral	Other				
	n Parlana da Raman	Arranteeded Class	Freesam 197	Klopent	Frances 1977	K	Freeson Noy	Kinyana	Finesan noy	Kångrams	Freedow New Y	Kitograms	Treesee Trees	Klopani	7 	Kington			
and .	Confidential	Aggregated class data	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0		0.0			
IMK	Amikacin	Aminophrosides	0	0.0	0	0.0	0	6.0	0	0.0	0	0.0	0	0.0	0	0.0			
MMX.	Amoxicitin	Penicitins	1	0.0	0	0.0	1	0.0	0	0.0	1	0.0	0	0.0	0	0.0			
INC	Amoxicillin - Clavulanic A	c Penicillins	1	3.8	0	0.0	1	3.8	0	0.0	1	3.8	0	0.0	0	0.0			
UMP.	Ampicillin	Penicillins	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0			
LAM	Ampicillin + Sulbectam	Penicillins	0	0.0	0	0.0	0	0.0	0	0.0	0	00	0	00	0	0.0			
UPR .	Apramycin	Aminoglycosides	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0			
UK.	Aspoxicillin	Penicitins	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	6.0	0	0.0			
101	Avilamycin	Onhosomycins	0	0.0	0	6.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0			
840	Avoparcin	Glycopeptides	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0			
1254	Azithromycin	Macrolides	0	0.0	0	6.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0			
SAC .	Bacitracin	Polypeptides	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0			

OIE AMU IT database: Timeline and Progress



AMU data collection: from a spreadsheet to a database



Future Development (AMU Database System)

X =

Country Data Ownership

- Specific trend analysis
- Raised awareness
- Increased transparency



- Automatic calculations
- Data quality check
- Detailed data analysis

Refinement of Information

- Species level data
- Farm level data

FT & K

- Connection with other data sources:
 - ✓ OIE-WAHIS (World Animal Health Information System)

FT & K

- ✓ TISSA (Tripartite Integrated System for Surveillance on AMR and Antimicrobial Use)
- ✓ PVS (Performance of Veterinary Services)

Expected actions

- Capacity building for the surveillance/monitoring of AMU in animals
- Sharing of AMU data publicly
- Implementation of AMU international standards

Thank you for your attention





Protecting animals, preserving our future



12, rue de Prony, 75017 Paris, France www.oie.int media@oie.int - oie@oie.int

ЪřС

World Organisation for Animal Health · Protecting animals, Preserving our future | 16